



HAL
open science

The insulin gene variable number of tandem repeat: associations and interactions with childhood body fat mass and insulin secretion in normal children.

Barbara Heude, Clive J. Petry, Alspac Study Team, Marcus Pembrey, David
B. Dunger, Ken K. Ong

► To cite this version:

Barbara Heude, Clive J. Petry, Alspac Study Team, Marcus Pembrey, David B. Dunger, et al.. The insulin gene variable number of tandem repeat: associations and interactions with childhood body fat mass and insulin secretion in normal children.: INS VNTR, fat mass and insulin secretion. *Journal of Clinical Endocrinology and Metabolism*, 2006, 91 (7), pp.2770-5. 10.1210/jc.2005-2055 . inserm-00175995

HAL Id: inserm-00175995

<https://inserm.hal.science/inserm-00175995>

Submitted on 2 Oct 2007

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

The insulin gene VNTR: associations and interactions with childhood body fat mass and insulin secretion

Short title: *INS* VNTR, fat mass and insulin secretion

Barbara Heude¹, Clive J Petry², the ALSPAC study team³, Marcus Pembrey⁴, David B
Dunger², Ken K Ong^{1,2}

¹Medical Research Council Epidemiology Unit, Cambridge, UK

²Department of Paediatrics, University of Cambridge, UK

³Unit of Paediatric and Perinatal Epidemiology, Department of Community Based
Medicine, University of Bristol, UK

⁴Clinical and Molecular Genetics Unit, Institute of Child Health, University College
London, UK

Correspondence to:

Dr Ken Ong

MRC Epidemiology Unit

Strangeways Research Laboratory, Wort's Causeway

Cambridge CB1 8RN UK

Tel: +44 1223 740 003

Fax: +44 1223 740050

Email: ken.ong@mrc-epid.cam.ac.uk

Abstract

Context Polymorphism at the insulin gene (*INS*) VNTR shows variable associations with childhood BMI in different populations.

Objective To study *INS* VNTR associations with body composition and insulin secretion in children.

Design Prospective birth cohort study

Participants 947 children genotyped for the *INS* VNTR

Main outcome measures Whole body DXA at 9 years to estimate height-corrected fat mass index (FMI), truncal fat index (TFI) and fat-free mass (FFM). Insulin secretion post-oral glucose at 8y.

Results Homozygous III/III children had higher BMI ($p=0.020$), FMI ($p=0.015$) and TFI ($p=0.022$) at 9y than class I bearers, but no difference in FFM ($p=0.23$). Gain in weight SD score between birth to 3y was positively associated with BMI, FMI and TFMI in class I bearers, but not in III/III children (p -interaction with genotype = 0.009 to 0.066). *INS* VNTR genotype was not overall associated with insulin secretion at 8y ($p=0.64$), but class I bearers showed a stronger positive correlation between insulin secretion and BMI at 8y (regression coefficient \pm SE: 0.26 ± 0.05 , $p<0.0001$) than III/III children (-0.10 ± 0.07 , $p=0.48$) (p -interaction=0.003).

Conclusion We clarified that the overall association between *INS* VNTR class III/III genotype and larger BMI in this population relates to fat mass, but not fat-free mass. In contrast, among the sub-group of children who showed rapid infancy weight gain, class I bearers tended to have larger BMI and fat mass than III/III children. This genetic interaction could relate to insulin secretion, which in class I bearers increased more rapidly with overweight and obesity.

Introduction

Hopes of preventing childhood obesity rely not only on effective interventions, but also on the early identification of those children who are at highest risk of becoming overweight or obese. Several studies have recently reported that rapid weight gain during early postnatal life predicts subsequent increased obesity risk during later childhood, and this risk persists in young adults (1-4). We hypothesised that childhood adiposity relates to both genetic factors and rate of early postnatal weight gain.

We recently reported confirmation of association between the insulin gene (*INS*) variable number of tandem repeat (VNTR) polymorphism and size at birth in the Avon Longitudinal Study of Parents and Children (ALSPAC), both by repeated association in a 2nd ALSPAC sub-group, and by demonstrating association with parental transmitted alleles (5). The class III alleles were recessively associated with larger head circumference at birth, higher cord blood levels of insulin-like growth factor-2, and those associations showed significant interaction with birth order and postnatal rapid weight gain, a marker of previous intra-uterine growth restriction.

In that study of normal representative UK children, we also observed that class III/III children had greater body weight, BMI and waist circumference at age 8 years; however those postnatal associations appeared to be reversed among the 25% of children who showed early postnatal rapid weight gain (5). Similarly, among obese French children the *INS* VNTR class I alleles, rather than the class III, were associated with increased BMI gains (6). A further study in obese children reported that the *INS* VNTR was a quantitative trait locus for the insulin response to oral glucose, and those

authors hypothesised that class I alleles could confer greater insulin secretion for the degree of BMI compared to class III alleles (7).

We have now reanalysed our existing *INS* VNTR genotype data in the ALSPAC children with new phenotype data on body composition at age 9 years, in order to distinguish between genetic associations with fat mass or lean mass. We also aimed to confirm the reported interactive effects of *INS* VNTR genotype and BMI on insulin secretion.

Methods

Subjects

As part of the ALSPAC study, previously described (8), the “Children in Focus” and “Control” sub-cohorts were measured at age 3 years, in addition to the whole ALSPAC cohort measurements at birth, 7 years and 9 years, when all children also had a whole body dual X-ray emission absorptiometry (DXA) scan. Analysis of body composition at age 9 years was based on 947 children with full data on DXA parameters, early growth phenotypes and *INS* VNTR genotype. Analysis of insulin secretion at age 8 years was based on 750 children with complete data. The subjects analysed in this paper did not differ from the whole ALSPAC cohort with respect to childhood growth at age 9 years (data provided to reviewers). Preparation of DNA and genotyping for *INS* VNTR were previously described (5).

Body composition

At age 9.9 (+/- 0.33) years all ALSPAC children were invited to attend for a 3-hour hands-on assessment. Height was measured with shoes and socks removed using a

Harpenden stadiometer (Holtain Ltd, Crymych, Pembs, UK). Weight was measured using a Tanita TBF 305 body fat analyser and weighing scales (Tanita UK Ltd, Yewsey, Middlesex, UK). Total fat (FM), central fat and lean mass (LM) were measured using a Lunar Prodigy DXA scanner (GE Medical Systems Lunar, Madison, WI, USA). The scans were visually inspected and realigned where necessary. Trunk fat mass was estimated using the automatic region of interest that included chest, abdomen and pelvis.

Body composition variables were corrected for differences in height by calculating the fat mass index (fat mass/ height²) and truncal fat mass index (truncal fat mass/ height²) (9).

Insulin secretion

At age 8 years (mean \pm SD: 8.2 \pm 0.1, range 8.0 to 8.5 years), 851 children (750 with *INS* VNTR genotype data) from the Children in Focus or Control sub-cohorts attended the research clinic in the morning after an overnight fast (10). Fasting was validated by questionnaire and data were excluded if they were taking oral steroids, or had any current infection. A venous blood sample was taken to measure glucose and insulin levels, before and 30-min after an oral glucose load (1.75 g/kg, maximum 75g) as a drink (Lucozade Energy Original, GlaxoSmithKline PLC, Greenford, Middlesex, UK).

Insulin sensitivity was estimated using the Homeostasis model computer program, kindly provided by Dr Jonathan Levy, University of Oxford, UK (11). Insulin secretion was calculated as the corrected insulin response from 30mins insulin and glucose levels: $[\text{Insulin}_{30} / (\text{Glucose}_{30} \times (\text{Glucose}_{30} - 3.9))] \text{ (mU/mmol}^2\text{)}$ (12).

Following oral glucose there is a dose-response relationship between glucose and

insulin (12), and this correction for the attained glucose level has been shown to correlate most closely with the first-phase insulin response (13). Similar results were found when insulin secretion was estimated using the insulinogenic index ($(\text{insulin}_{30} - \text{insulin}_0) / (\text{glucose}_{30} - \text{glucose}_0)$) (14).

Statistical analysis

All data were explored for normality of distribution and log transformed where appropriate. The association between genotype and phenotype was analysed using a linear regression model under both global and recessive models.

For the association with DXA, adjustment was performed on age, gender, parity, education level of the mother and change in weight between birth and 3 years.

Interaction between genotype and postnatal weight gain was examined by introducing and testing the interactive term (genotype \times weight gain) in the previous models.

Adjusted regression coefficients are shown separately for each genotype group.

The association between genotype and insulin secretion at 8 years was examined adjusting for age, gender and BMI at 8 years. The interaction effect between BMI and genotype was analysed introducing and testing the interactive term (genotype \times BMI).

Analyses were performed using SPSS for Windows version 11.0 (SPSS, Chicago, IL).

Results

Mean body size and body composition at age 9 years are displayed by genotype in Table 1. Overall, homozygous III/III children had larger body weight, BMI, fat mass index and truncal fat mass index at age 9 years than class I bearers ($p=0.01$ to 0.02), but there was no difference in fat-free mass (Table 1).

Rate of early postnatal weight gain between birth to 3 years was positively associated with BMI at age 9 years in class I/I and I/III children ($p<0.0001$), but not in III/III children ($p=0.74$); and the difference in regression slopes between class I bearers and homozygous III/III children was significant, (p -interaction with genotype= 0.009 ; Table 2, Figure 1). Similarly, rate of weight gain between birth to 3 years was positively associated with fat mass index at age 9 years in class I bearers ($p<0.0001$), but not in III/III children ($p=0.68$), (p -interaction= 0.064 ; Table 2).

Mean fasting insulin levels, insulin sensitivity and parameters of insulin secretion at age 8 years are displayed by genotype in Table 3. No differences in mean values were observed between genotypes. However, in class I bearers insulin secretion showed a much closer correlation with BMI at 8 years than in homozygous III/III children (p -interaction= 0.003 ; Table 3; Figure 2). A closer correlation between insulin secretion and insulin sensitivity was also seen in class I bearers (I/I: $r= -0.22$, $p<0.0001$; I/III: $r= -0.31$, $p<0.0001$) than in homozygous III/III children (III/III: $r=0.09$, $p=0.6$) (p -interaction= 0.01).

Discussion

In this representative cohort of UK children the *INS* VNTR class III/III genotype was associated with increased childhood body fat mass in the overall population. These results do not represent independent confirmation of our previous reported association between *INS* VNTR with BMI at age 8 years in this same group of subjects (5), however they clarify that the association is with body fat mass rather than lean mass. Furthermore, we provide significant confirmation of two recently reported genetic interactions, which many go some way towards explaining the different *INS* VNTR genotype associations seen in different childhood sub-groups. First, as we previously observed (5), the III/III genotype association with larger size was particularly seen among those children who did not gain weight rapidly during infancy. In contrast, with increasing rate of early postnatal weight gain class I bearers, but not III/III genotype children, had larger BMI and fat mass at age 9 years. Secondly, similar to another previous study (7), we found that in class I bearers insulin secretion increased significantly more rapidly with increasing BMI compared to class III/III children.

In childhood populations obesity risk has been variably associated with either class III or class I *INS* VNTR alleles. Among children with early onset obesity those with the class I allele had greater BMI gains (6), and class I allele have been associated with overweight in a further French childhood growth study (15); in contrast in another study of non-obese girls the III/III homozygotes had greater fat mass by DXA (16). Recent adult population studies the *INS* VNTR showed no overall association with obesity risk (17, 18). Our findings of genetic interaction with early postnatal weight gain on subsequent BMI and body composition could provide a possible explanation for these contrasting reports. Our findings could suggest two separate pathways to

later obesity risk: rapid infant weight gain associated with the *INS* VNTR class I allele, and non-rapid infant weight gain associated with the III/III genotype. Genetic association studies for obesity should consider such potential interactions with early postnatal weight gain.

A further complexity is that effects of *INS* VNTR alleles may differ according to parent-of origin (19). Among French children with early onset obesity, those who inherited a class I allele from their father (but not from their mother) had a 1.8-fold increased risk of obesity (20). Our studies in this ALSPAC sub-cohort do not have sufficient power to explore parent-of-origin effects (5). Selection of children with extreme early-onset obesity would also provide much greater power to detect the class I association with obesity, however population-based studies are more generalisable and may be more likely to confirm interactive effects with the wider range of early growth trajectories.

Our studies have consistently shown apparent recessive effects of class III alleles on size at birth, childhood growth and IGF2 protein levels at birth (5, 21), and the mean values and regression coefficients reported here in I/I and I/III children were near identical. However, other studies have found apparent dominant effects of class III alleles (7, 22, 23). Recently Rodriguez et al. reported confirmation of associations with a haplotype in IGF2-INS-TH region tagged by *INS* VNTR class I alleles, together with allele A of *IGF2* *ApaI*, and allele 9 of *TH01*, with both lower BMI and lower insulin secretion in adult men from two population-based UK cohorts (24, 25). Thus, the genetic associations we observed could possibly be explained by specific

sub-types of *INS* VNTR allele class, or by linkage disequilibrium with other neighbouring variants (26).

The *INS* VNTR could directly influence postnatal body size by altering *INS* or *IGF2* transcription *in utero* (23, 27), or during postnatal life. The increased type 1 diabetes risk associated with class I alleles (22, 26) has been attributed to reduced fetal thymic insulin mRNA expression leading to loss of immune tolerance to insulin (23, 28). In contrast to those studies in the thymus, in transfected pancreatic cell lines and fetal pancreas class I alleles are associated with increased insulin mRNA expression (29)(30). Polymorphism at the *INS* VNTR minisatellite may alter a transcription promoter binding site (31), and transfection of class I alleles has been reported to influence alternative splicing of *INS* intron 1 resulting in longer, mature mRNA transcripts and higher proinsulin levels (32). In adults class I allele are associated with pulsatility of beta-cell insulin secretion (33).

Thus, it is possible that the class I allele, could confer a greater responsiveness in insulin secretion to changes in BMI and insulin sensitivity, and therefore a predisposition to storing adipose rather than lean tissue during periods of rapid weight gain, or in obese children (6). This could predispose to future type 2 diabetes, in particular related to the development of insulin resistance. Conversely, relatively lower insulin secretion in class III/III subjects in the face of increasing BMI or insulin resistance could also contribute to increased type 2 diabetes risk (34). Recent large studies in adults have shown no overall influence of *INS* VNTR genotype on type 2 diabetes risk (35). However, similar to obesity risk, we hypothesise that the

pathogenesis and phenotype of type 2 diabetes could differ according to both early weight gain patterns and *INS* VNTR genotype.

In conclusion, in these representative children the *INS* VNTR class III/III genotype was overall associated with increased adiposity. However significant genetic interactions were seen with BMI and insulin secretion that could also support a class I allele predisposition to obesity following rapid infant weight gain. Different *INS* VNTR genotypes and patterns of early postnatal weight gain could underlie discrete developmental pathways to obesity and type 2 diabetes risks.

Acknowledgments

We are extremely grateful to all the children and parents who took part in the study and to the midwives for their co-operation and help in recruitment. ALSPAC is supported by the Medical Research Council (MRC), the Wellcome Trust, the Department of Health, the Department of the Environment, the European Commission, and many others. DD is supported by the Wellcome Trust and the Juvenile Diabetes Research Foundation.

Table 1: Body size and body composition at age 9 years, stratified by *INS* VNTR genotype.

	I/I	I/III	III/III	p-values	
	N=460	N=420	N=67	p1	p2
Weight (Kg)	34.7 (34.1, 35.3)	34.6 (34.0, 35.2)	36.7 (35.1, 38.2)	0.048	0.015
Height (cm)	139.4 (138.9, 140.0)	139.2 (138.7, 139.8)	140.3 (139.0, 141.6)	0.64	0.16
BMI (Kg/m ²)	17.6 (17.3, 17.8)	17.5 (17.3, 17.8)	18.4 (17.6, 18.9)	0.072	0.020
Fat mass index (Kg/m ²)	3.78 (3.63, 3.97)	3.67 (3.49, 3.86)	4.35 (3.86, 4.85)	0.077	0.015
Truncal fat index (Kg/m ²)	1.45 (1.38, 1.54)	1.40 (1.32, 1.48)	1.68 (1.46, 1.93)	0.065	0.022
Fat free mass (Kg)	24.3 (24.1, 24.1)	24.3 (24.1, 24,6)	24.9 (24.3, 25.6)	0.26	0.23

Results are Means or Geometric Means (95% CI), and are adjusted for age, gender, mother's education level, parity and weight change between 0 to 3 years.

p1: Difference between means under the global model (I/I vs. I/III vs. III/III)

p2: Difference between means under the recessive model (III/III vs. I/I and I/III)

Table 2: Correlations between early postnatal weight gain (change in weight SD score from birth to 3 years) and body size and composition at 9 years, stratified by *INS* VNTR genotype.

	I/I	I/III	III/III	p-interaction	
<i>Correlation with weight gain</i>				p1	p2
<i>0-3y:</i>					
Weight at 9y (Kg)	2.88 ± 0.29**	3.19 ± 0.29**	1.32 ± 1.12	0.086	0.037
Height at 9y (cm)	2.24 ± 0.25**	2.19 ± 0.25**	1.94 ± 0.75*	0.90	0.94
BMI at 9y (Kg/m ²)	0.89 ± 0.11**	1.08 ± 0.12**	0.08 ± 0.45	0.025	0.009
Fat mass index at 9y (Kg/m ²)	0.68 ± 0.09**	0.73 ± 0.10**	0.04 ± 0.37	0.049	0.066
Truncal fat index at 9y (Kg/m ²)	0.35 ± 0.05**	0.37 ± 0.05**	0.02 ± 0.19	0.17	0.064
Fat free mass at 9y (Kg)	1.12 ± 0.12**	1.33 ± 0.12**	0.83 ± 0.40*	0.23	0.31

Regression coefficients are displayed (\pm SE), adjusted for age, gender, mother's education level, and parity.

P-values for regression coefficients within each group: * $p < 0.05$; ** $p < 0.0001$

P-interaction: p1: Difference between regression coefficients under the global model

(I/I vs. I/III vs. III/III); p2: Difference between regression coefficients under the

recessive model (III/III vs. I/I and I/III)

Table 3: Insulin sensitivity and secretion at 8 years, stratified by *INS* VNTR genotype.

	I/I	I/III	III/III	p-values	
	N=349	N=341	N=60	p1	p1
Fasting insulin (mU/l)	5.1 (4.8, 5.5)	5.2 (4.9, 5.6)	5.2 (4.4, 6.2)	0.86	0.90
Fasting glucose (mmol/l)	4.9 (4.9, 5.0)	5.0 (4.9, 5.0)	5.0 (4.9, 5.1)	0.66	0.44
Insulin sensitivity (%HOMA)	189 (177, 201)	185 (173, 197)	183 (156, 213)	0.87	0.82
Corrected insulin response (mU/mmol ²)	1.38 (1.27, 1.51)	1.39 (1.27, 1.52)	1.49 (1.20, 1.84)	0.83	0.55
Insulinogenic index (mU/mmol)	12.7 (11.7, 13.9)	13.2 (12.0, 14.4)	14.4 (11.6, 17.8)	0.58	0.36

Results are Means or Geometric Means (95% CI), adjusted for age and gender.

p1: Difference between means under the global model (I/I vs. I/III vs. III/III)

p2: Difference between means under the recessive model (III/III vs. I/I and I/III)

Table 4: Correlations between BMI at 8 years and indices of insulin sensitivity and insulin secretion at 8 years, stratified by *INS* VNTR genotype.

	I/I	I/III	III/III	p-interaction	
				p1	p2
<i>Correlations with BMI at 8y:</i>					
Insulin sensitivity (%HOMA)	-17.6 ± 2.7**	-13.2 ± 2.4**	-14.2 ± 5.1*	0.72	0.92
Corrected insulin response (mU/mmol ²)	0.24 ± 0.05**	0.29 ± 0.05**	-0.10 ± 0.07	0.011	0.003
Insulinogenic index (mU/mmol)	1.48 ± 0.29	1.52 ± 0.26	-0.64 ± 0.75	0.015	0.004

Regression coefficients are displayed (\pm SE), adjusted for age and gender.

P-values for regression coefficients within each group: * $p < 0.05$; ** $p < 0.0001$

P-interaction: p1: Difference between regression coefficients under the global model

(I/I vs. I/III vs. III/III); p2: Difference between regression coefficients under the

recessive model (III/III vs. I/I and I/III)

Figure 1: BMI at age 9 years was positively related to early postnatal weight gain (change in weight SD score from birth to 3 years) in *INS* VNTR class I bearers (I/I and I/III: $p < 0.0001$, $N = 880$) but not in III/III children ($p = 0.74$, $N = 67$) (p -interaction with genotype = 0.009).





Figure 2: Insulin secretion at age 8 years (corrected insulin response) was positively related to BMI at age 8 years in *INS* VNTR class I bearers (I/I and I/III, $p < 0.0001$, $N = 690$) but not in III/III children ($p = 0.48$, $N = 60$) (p -interaction = 0.003).



References

1. **Ong KK, Ahmed ML, Emmett PM, Preece MA, Dunger DB, the-ALSPAC-Study-Team** 2000 Association between postnatal catch-up growth and obesity in childhood: prospective cohort study. *BMJ* 320:967-971
2. **Stettler N, Zemel BS, Kumanyika S, Stallings VA** 2002 Infant weight gain and childhood overweight status in a multicenter cohort study. *Pediatrics* 109:194-199
3. **Stettler N, Kumanyika SK, Katz SH, Zemel BS, Stallings VA** 2003 Rapid weight gain during infancy and obesity in young adulthood in a cohort of African Americans. *Am J Clin Nutr* 77:1374-8
4. **Ekelund U, Ong K, Linne Y, Neovius M, Brage S, Dunger DB, Wareham NJ, Rossner S** 2004 Both infancy and childhood weight gain predict obesity risk at age 17 years: Prospective birth cohort study (SWEDES). *Obes Res* 12:A186
5. **Ong KK, Petry CJ, Barratt BJ, Ring S, Cordell HJ, Wingate DL, Pembrey ME, Todd JA, Dunger DB** 2004 Maternal-fetal interactions and birth order influence insulin variable number of tandem repeats allele class associations with head size at birth and childhood weight gain. *Diabetes* 53:1128-33
6. **Le Stunff C, Fallin D, Schork NJ, Bougneres P** 2000 The insulin gene VNTR is associated with fasting insulin levels and development of juvenile obesity. *Nat Genet* 26:444-446
7. **Dos Santos C, Fallin D, Le Stunff C, LeFur S, Bougneres P** 2004 INS VNTR is a QTL for the insulin response to oral glucose in obese children. *Physiol Genomics* 16:309-13
8. **Golding J, Pembrey ME, Jones R** 2001 ALSPAC--the Avon Longitudinal Study of Parents and Children. I. Study methodology. *Paediatr Perinat Epidemiol* 15:74-87
9. **Wells JC, Cole TJ** 2002 Adjustment of fat-free mass and fat mass for height in children aged 8 y. *Int J Obes Relat Metab Disord* 26:947-52
10. **Ong KK, Petry CJ, Emmett PM, Sandhu MS, Kiess W, Hales CN, Ness AR, the-ALSPAC-study-team, Dunger DB** 2004 Insulin sensitivity and secretion in normal children related to size at birth, postnatal growth, and plasma insulin-like growth factor-I levels. *Diabetologia* 47:1064-1070
11. **Levy JC, Matthews DR, Hermans MP** 1998 Correct homeostasis model assessment (HOMA) evaluation uses the computer program. *Diabetes Care* 21:2191-2192
12. **Sluiter WJ, Erkelens DW, Reitsma WD, Doorenbos H** 1976 Glucose tolerance and insulin release, a mathematical approach I. Assay of the beta-cell response after oral glucose loading. *Diabetes* 25:241-244
13. **Hanson RL, Pratley RE, Bogardus C, Venkat Narayan KM, Roumain JM, Imperatore G, Fagot Campagna A, Pettitt DJ, Bennett PH, Knowler WC** 2000

- Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. *Am J Epidemiol* 151:190-198
14. **Phillips DI, Clark PM, Hales CN, Osmond C** 1994 Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. *Diabet Med* 11:286-292
 15. **Heude B, Dubois S, Charles MA, Deweirder M, Dina C, Borys JM, Ducimetiere P, Froguel P** 2004 VNTR polymorphism of the insulin gene and childhood overweight in a general population. *Obes Res* 12:499-504
 16. **Thorsby PM, Berg JP, Birkeland KI** 2005 Insulin gene variable number of tandem repeats is associated with increased fat mass during adolescence in non-obese girls. *Scand J Clin Lab Invest* 65:163-8
 17. **Bennett A, Sovio U, Ruukonen A, Martikainen H, Pouta A, Taponen S, Hartikainen AL, Franks S, Peltonen L, Elliott P, Jarvelin MR, McCarthy MI** 2005 No association between insulin gene variation and adult metabolic phenotypes in a large Finnish birth cohort. *Diabetologia* 48:886-91
 18. **Sandhu MS, Heude B, Young EH, Luben R, Luan J, Khaw KT, Todd J, Wareham NJ** 2005 INS VNTR class genotype and indexes of body size and obesity: population-based studies of 7,999 middle-aged men and women. *Diabetes* 54:2812-5
 19. **Moore GE, Abu-Amero SN, Bell G, Wakeling EL, Kingsnorth A, Stanier P, Jauniaux E, Bennett ST** 2001 Evidence that insulin is imprinted in the human yolk sac. *Diabetes* 50:199-203
 20. **Le Stunff C, Fallin D, Bougneres PF** 2001 Paternal transmission of the very common class I INS VNTR alleles predisposes to childhood obesity. *Nat Genet* 29:96-99
 21. **Dunger DB, Ong KK, Huxtable SJ, Sherriff A, Woods KA, Ahmed ML, Golding J, Pembrey ME, Ring S, Bennett ST, Todd JA** 1998 Association of the *INS* VNTR with size at birth. *Nat Genet* 19:98-100
 22. **Bennett ST, Lucassen AM, Gough SC, Powell EE, Undlien DE, Pritchard LE, Merriman ME, Kawaguchi Y, Dronsfield MJ, Pociot F, al e** 1995 Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. *Nat Genet* 9:284-292
 23. **Bennett ST, Wilson AJ, Cucca F, Nerup J, Pociot F, McKinney PA, Barnett AH, Bain SC, Todd JA** 1996 *IDDM2*-VNTR-encoded susceptibility to type 1 diabetes: dominant protection and parental transmission of alleles of the insulin gene-linked minisatellite locus. *J Autoimmun* 9:415-421
 24. **O'Dell SD, Bujac SR, Miller GJ, Day IN** 1999 Associations of IGF2 ApaI RFLP and INS VNTR class I allele size with obesity. *Eur J Hum Genet* 7:821-7

25. **Rodriguez S, Gaunt TR, Dennison E, Chen XH, Syddall HE, Phillips DI, Cooper C, Day IN** 2006 Replication of IGF2-INS-TH(*)5 haplotype effect on obesity in older men and study of related phenotypes. *Eur J Hum Genet* 14:109-16
26. **Barratt BJ, Payne F, Lowe CE, Hermann R, Healy BC, Harold D, Concannon P, Gharani N, McCarthy MI, Olavesen MG, McCormack R, Guja C, Ionescu-Tirgoviste C, Undlien DE, Ronningen KS, Gillespie KM, Tuomilehto-Wolf E, Tuomilehto J, Bennett ST, Clayton DG, Cordell HJ, Todd JA** 2004 Remapping the insulin gene/IDDM2 locus in type 1 diabetes. *Diabetes* 53:1884-9
27. **Paquette J, Giannoukakis N, Polychronakos C, Vafiadis P, Deal C** 1998 The *INS* 5' variable number of tandem repeats is associated with *IGF2* expression in humans. *J Biol Chem* 273:14158-14164
28. **Pugliese A, Zeller M, Fernandez A, Jr., Zalberg LJ, Bartlett RJ, Ricordi C, Pietropaolo M, Eisenbarth GS, Bennett ST, Patel DD** 1997 The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the *INS VNTR-IDDM2* susceptibility locus for type 1 diabetes. *Nat Genet* 15:293-297
29. **Lucassen AM, Sreaton GR, Julier C, Elliott TJ, Lathrop M, Bell JI** 1995 Regulation of insulin gene expression by the IDDM associated, insulin locus haplotype. *Hum Mol Genet* 4:501-506
30. **Vafiadis P, Bennett ST, Colle E, Grabs R, Goodyer CG, Polychronakos C** 1996 Imprinted and genotype-specific expression of genes at the *IDDM2* locus in pancreas and leucocytes. *J Autoimmun* 9:397-403
31. **Catasti P, Chen X, Moyzis RK, Bradbury EM, Gupta G** 1996 Structure-function correlations of the insulin-linked polymorphic region. *J.Mol.Biol.* 264:534-545
32. **Kralovicova J, Gaunt TR, Rodriguez S, Wood PJ, Day IN, Vorechovsky I** 2006 Variants in the Human Insulin Gene That Affect Pre-mRNA Splicing: Is -23HphI a Functional Single Nucleotide Polymorphism at IDDM2? *Diabetes* 55:260-4
33. **Ahmed S, Bennett ST, Huxtable SJ, Todd JA, Matthews DR, Gough SC** 1999 *INS VNTR* allelic variation and dynamic insulin secretion in healthy adult non-diabetic Caucasian subjects. *Diabet Med* 16:910-917
34. **Huxtable SJ, Saker PJ, Haddad L, Walker M, Frayling TM, Levy JC, Hitman GA, O'Rahilly S, Hattersley AT, McCarthy MI** 2000 Analysis of parent-offspring trios provides evidence for linkage and association between the insulin gene and type 2 diabetes mediated exclusively through paternally transmitted class III variable number tandem repeat alleles. *Diabetes* 49:126-130
35. **Mitchell SM, Hattersley AT, Knight B, Turner T, Metcalf BS, Voss LD, Davies D, McCarthy A, Wilkin TJ, Smith GD, Ben-Shlomo Y, Frayling TM** 2004 Lack of support for a role of the insulin gene variable number of tandem repeats minisatellite (*INS-VNTR*) locus in fetal growth or type 2 diabetes-related intermediate traits in United Kingdom populations. *J Clin Endocrinol Metab* 89:310-7